简介:
In September 1999, gene therapy research ground to a halt with the tragic death of Jesse Gelsinger. Twenty years on, large pharmaceutical firms are fiercely vying for new gene therapy candidates and manufacturing capabilities.In August, for instance, Pfizer invested US$500 million into the construction of a gene therapy manufacturing site. The move follows Pfizer’s $600 million acquisition of Bamboo Therapeutics, a biotech with an adeno-associated virus (AAV) gene therapy platform, in 2016.Pfize